Reliable GLP-1 Aggregate Analysis Using Biozen dSEC
As peptide-based therapeutics continue to expand, understanding and controlling aggregation behavior has become essential for ensuring drug safety and efficacy. This webinar provides a focused exploration of peptide aggregation mechanisms and how Size Exclusion Chromatography (SEC) can be applied to characterize these critical quality attributes. Attendees will be introduced to the separation principles behind SEC and learn how Biozen dSEC‑1 can improve peptide aggregate detection and quantification. Real-world applications will cover aggregation profiles of key GLP‑1 receptor agonists including semaglutide, liraglutide, and tirzepatide.
Key Learning Points
- Learn about the fundamentals of peptide aggregation
- Find the separation mechanism of Size Exclusion Chromatography (SEC)
- Identify the key features and advantages of the Biozen dSEC‑1 column
- Discuss the use of Biozen dSEC-1 for aggregate analysis of GLP-1 agonists (Semaglutide, Liraglutide, and Tirzepatide)
Who Should Attend
- Any LC users working with or interested in analyzing peptide therapeutics by HPLC.
Speaker: Lucia Geis Asteggiante (Senior Technical Specialist, Phenomenex)
Lucia is a Senior Technical Specialist that has recently joined Phenomenex’s Global Technical Team. She has a broad experience in the field of Analytical Chemistry with a particular focus on LC chromatography coupled with mass spectrometry. Lucia comes from a strong academic and regulatory background with experiences ranging from method development and analysis of small molecules to large protein complexes. She gained her Ph.D. at the University of Maryland - College Park, USA and did her post-doctoral work at the University of Oxford, UK. During her time as a researcher, she has authored/co-authored 23 scientific publications and 2 book chapters.
